Videos
Full laboratory tour of the KCAS Bio location in Kansas City, KS USA.
Videos
Full laboratory tour of the KCAS Bio location in Kansas City, KS USA.
Videos
Full laboratory tour of the KCAS Bio location in Philadelphia, PA USA.
Podcasts
In this special 100th episode of The Weekly Bioanalysis, hosts John Perkins and Dominic Warrino are joined on camera by KCAS Bio CEO John Bucksath and Chief Commercial Officer Amy Mize to celebrate a major milestone. Together, they reflect on the podcast’s origins during the uncertainty of the COVID-19…
News
KCAS Bio is pleased to announce that Dr Mouhssin Oufir, General Manager of KCAS Bio Lyon, was recently featured on Paroles d’Entreprises, broadcast on BFM Business and hosted by Vincent Touraine. During the interview, he shared insights into how the group KCAS Bio supports pharmaceutical and…
Podcasts
On this latest episode of The Weekly Bioanalysis podcast, Dom and John dive into one of the most pressing challenges in modern bioanalysis: how to break down silos and drive better project execution through continuity across teams. Drawing from real-world experience, they explore how the industry has evolved from…
Blogs
The world of medicine relies heavily on innovation, and Contract Research Organizations (CROs) are key players behind the scenes. But what exactly is a CRO, and why are these organizations so crucial to the development of new therapies and medical advancements? Let’s explore what CROs do and why they’re…
Podcasts
In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to…
Podcasts
In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and…
Blogs
Bioanalysis sits at the intersection of science, regulation, and application. As therapeutic modalities grow more complex and development timelines compress, the role of bioanalysis continues to expand beyond data generation into strategic enablement. To better understand what lies ahead, we asked a diverse group of leaders across KCAS…
Blogs
Global drug development now operates across borders by default. Pharmaceutical and biotech R&D routinely spans multiple countries, driven by competitive timelines, access to patients, and the need for specialized expertise. Governments have responded by actively courting development programs through incentives, talent investment, and streamlined infrastructure. Australia remains a strong…
Podcasts
John and Dom introduce guest Brad Nawa (Alamar Biosciences) to explain the NULISA™ platform, an ultra-sensitive platform for protein quantitation that aims to outperform earlier “ultra-sensitive” tools that often didn’t translate well in practice. Brad notes the platform is still antibody/content-driven, but differentiates itself by reducing background through a…